Furthermore, a post hoc analysis was conducted in 52 NSCLC patients with EGFR-mutation and CNS metastases who received furmonertinib treatment ranging from 40 mg/d to 240 mg/d. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.